Plk1 and AKA, alone or together with Wee1, are attractive therapeutic targets in neoplastic mast cells according to a study presented by Manuela Mancini et al at the 23rd Congress of European Hematology Association (EHA) (Free EHA Whitepaper) (Abstracts, EHA (Free EHA Whitepaper) 2018, The European Hematology Association (EHA) (Free EHA Whitepaper), JUN 11, 2018, View Source [SID1234527258]). Repurposing Plk1 or AKA±Wee1 inhibitors in advanced clinical development for other indications is a therapeutic strategy worth to be explored in an attempt to improve the outcome of patients with advanced systemic mastocytosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!